Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma
Author:
Servin-Rojas MaximilianoORCID,
Fong Zhi Ven,
Fernandez-Del Castillo Carlos,
Ferrone Cristina R.,
Lee HangORCID,
Lopez-Verdugo Fidel,
Qiao Guoliang,
Rocha-Castellanos Dario M.ORCID,
Lillemoe Keith D.,
Qadan MotazORCID
Reference24 articles.
1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021
2. Detection, treatment, and survival of pancreatic cancer recurrence in the Netherlands: a nationwide analysis;Daamen;Ann Surg,2022
3. Surgery for recurrent pancreatic cancer: is it effective?;Moletta;Cancers (Basel),2019
4. Total neoadjuvant therapy with FOLFIRINOX in combination with Losartan Followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial;Murphy;JAMA Oncol,2019
5. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial;Jang;Ann Surg,2018
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献